Information provided in the product description is from published literature. Due to the nature of scientific experimentation, your results (e.g., selectivity and effective concentrations) or specific application for this product may differ. If you have questions about how this product fits your application, please contact our technical support staff.
Visit our FAQ
Toll Free Phone (USA and Canada Only): (888) 526-5351
Direct Phone: (734) 975-3888
Provide batch numbers separated by commas to download or request available product inserts, QC sheets, certificates of analysis, data packs, and GC-MS data.
Resolvins are a family of potent lipid mediators derived from both eicosapentaenoic acid (EPA; Item No. 90110) and docosahexaenoic acid (DHA; Item No. 90310).1 In addition to being anti-inflammatory, resolvins promote the resolution of the inflammatory response back to a non-inflamed state.2 Resolvin D2 (RvD2) is produced physiologically from the sequential oxygenation of DHA by 15- and 5-lipoxygenase and functions to dampen excessive neutrophil trafficking to sites of inflammation.3 It reduces zymosan-stimulated PMN infiltration by 70% at doses as low as 10 pg per mouse and significantly reduces PAF-stimulated leukocyte adherence and emigration at 1 nM.3 Also, by stimulating nitric oxide production, RvD2 dose dependently decreases leukocyte-endothelial interactions. In a mouse model of sepsis, RvD2 reduces leukocyte and PMN infiltration, decreases production of pro-inflammatory cytokines, and promotes phagocyte-mediated bacterial clearance.3
WARNING This product is not for human or veterinary use.
1. Novel docosatrienes and 17S-
2. Resolvins and protectins in the termination program of acute inflammation. Trends Immunol. 28(4), 176-183 (2007).
3. Resolvin D2 is a potent regulator of leukocytes and controls microbial sepsis. Nature 461(7268), 1287-1291 (2009).
Analytical strategy for oxylipin annotation by combining chemical derivatization-
Human and mouse eosinophils differ in their ability to biosynthesize eicosanoids, docosanoids, the endocannabinoid 2-
High levels of eicosanoids and docosanoids in the lungs of intubated COVID-
Resolvin D1 and D2 reduce SARS-
Quantitative profiling of inflammatory and pro-
Lipid storm within the lungs of severe COVID-
Anti-
Apolipoprotein A-
Development of an optimized LC-
Lipid Mediator Metabolomics via LC-
Comprehensive high-
Myeloid cell hypoxia-
Determination of ω-